Shares of TG Therapeutics Inc. (NASDAQ:TGTX) traded up 2.2% during trading on Wednesday . The stock traded as high as $6.15 and last traded at $6.14, with a volume of 86,651 shares traded. The stock had previously closed at $6.01.

Several analysts have recently commented on the stock. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research note on Wednesday, May 4th. Brean Capital restated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, June 7th. Roth Capital restated a “buy” rating and issued a $33.00 target price on shares of TG Therapeutics in a research note on Thursday, June 9th. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Finally, SunTrust Banks Inc. assumed coverage on shares of TG Therapeutics in a research note on Friday, May 27th. They issued a “buy” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $22.75.

The company’s 50 day moving average is $5.96 and its 200 day moving average is $7.74. The company’s market capitalization is $329.46 million.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. On average, equities analysts forecast that TG Therapeutics Inc. will post ($1.23) EPS for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund increased its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 as of its most recent SEC filing.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.